Shelley Moore joins BioPlus
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has appointed a new regional director.
The company said that Shelley Moore will be responsible for business development in Tennessee. Moore, a registered nurse, brings six years of nursing experience, along with a career specialty in bleeding disorders, to her position at BioPlus.
"BioPlus’ best-in-class bleeding disorders program is a new high-touch intervention to provide care and support for the patient and caregiver, clear cost savings to the payer, and optimal clinical outcomes," BioPlus chief strategy officer Russell Gay said. "Shelley is leading our program in Tennessee using her many years of support in the community and her nursing skills to improve the quality of life for our patients."
Ranbaxy launches Caduet authorized generic
PRINCETON, N.J. — Days after its launch of a generic version of Pfizer’s cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.
Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.
An authorized generic is a branded drug launched under its generic name at a reduced price, usually by a third-party company under contract with the original manufacturer, to coincide with the marketing of the Food and Drug Administration-approved generic.
Caduet had sales of $339 million during the 12-month period ended in September, according to IMS Health.
Pfizer’s Toviaz safe, effective in treating overactive bladder in elderly patients
NEW YORK — A drug made by Pfizer appears to work in treating symptoms of overactive bladder in elderly patients, according to results of a clinical trial released Monday.
Pfizer said that results of study A0221049 of the drug Toviaz (fesoterodine fumarate) worked better than placebo in reducing the number of urgency urinary incontinence episodes. The 12-week study enrolled 562 elderly people in the United States. The drug already has Food and Drug Administration approval for treating overactive bladder.
"For older individuals with overactive bladder, incontinence accompanied by urgency is the symptom that is most bothersome and embarrassing and greatly impacts their overall quality of life," said Steven Romano, Pfizer SVP and head of the medicines development group of the company’s global primary care business unit. "Importantly, this was the first study of any antimuscarinic agent to demonstrate efficacy and safety in the rapidly growing population of medically vulnerable seniors who struggle with overactive bladder."